- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/575 - Hormones
Patent holdings for IPC class C07K 14/575
Total number of patents in this class: 1520
10-year publication summary
|
115
|
134
|
117
|
128
|
118
|
115
|
110
|
81
|
88
|
59
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novo Nordisk A/S | 2282 |
55 |
| Eli Lilly and Company | 3842 |
30 |
| Sanofi | 4055 |
30 |
| Zealand Pharma A/S | 258 |
25 |
| Janssen Pharmaceutica N.V. | 3392 |
23 |
| Protagonist Therapeutics, Inc. | 138 |
22 |
| Hanmi Science Co., Ltd. | 134 |
17 |
| The Regents of the University of California | 19918 |
15 |
| University of Miyazaki | 135 |
15 |
| H. Lundbeck A/S | 1247 |
15 |
| The General Hospital Corporation | 4733 |
14 |
| Dana-Farber Cancer Institute, Inc. | 2571 |
14 |
| Hanmi Pharm. Co., Ltd. | 570 |
14 |
| I2o Therapeutics, Inc. | 31 |
14 |
| Lipoxen Technologies Limited | 48 |
12 |
| Ip2ipo Innovations Limited | 171 |
12 |
| Boehringer Ingelheim International GmbH | 4650 |
11 |
| Centre National de La Recherche Scientifique | 10418 |
11 |
| Amgen Inc. | 4074 |
11 |
| President and Fellows of Harvard College | 5976 |
11 |
| Other owners | 1149 |